NMN and NR Supplementation in Human Trials

Human trials of NMN and NR supplementation answer one question clearly and leave a harder one open. Both compounds reliably raise blood NAD+, but that biochemical change has not translated into broad, proven health benefits. The studies show small signs of benefit in specific areas that need more study, but they do not show that these supplements slow human aging.

Why NAD+ decline is the starting premise, not the conclusion, for NMN and NR research

NAD+ is a coenzyme involved in several basic jobs that keep cells functioning. Through its reduced form, NADH, it fuels the electron transport chain that supports energy production. It also activates sirtuin deacylases, which regulate gene expression and stress responses, and fuels PARP enzymes that repair DNA strand breaks. These are central tasks. That breadth explains why NAD+ has become an organizing idea in aging biology.

NAD+ levels fall with age, though how much they fall differs from person to person and tissue to tissue. That decline correlates with reduced mitochondrial efficiency, impaired DNA repair, and increased inflammatory signaling. If lower NAD+ contributes to these problems, restoring it might slow some of the cellular dysfunction associated with aging. But the biological importance of a substance does not establish that taking more of its precursors improves health.

NMN and NR are vitamin B3 derivatives that feed into the NAD+ salvage pathway. Within cells, NR is converted to NMN, which is then converted to NAD+, so their pathways partly overlap. Mouse studies gave researchers a reason to investigate further, reporting improvements in muscle function, cardiovascular performance, insulin sensitivity, and lifespan in some strains. Mice age faster and often respond differently to interventions, with resveratrol offering a familiar caution about translating animal findings into human expectations.

What the first wave of human trials confirmed — and what it did not

Yi and colleagues’ randomized, multicenter, double-blind, placebo-controlled trial in GeroScience found dose-dependent increases in blood NAD+ with NMN in healthy middle-aged adults. The trial also established a safety and tolerability profile at multiple doses under the conditions studied. Similar NAD+ elevation is the most replicated finding across human NMN and NR research. This is a real biochemical result. It establishes the first step in the proposed argument, which is that supplementation can change the system it is intended to influence.

The second step is harder to establish. Blood NAD+ is a surrogate marker. Its level may not reflect intracellular NAD+ in muscle, brain, or liver, where the aging-related functions of interest take place. Does a higher blood reading mean those tissues work better? Without functional measurements, the blood result cannot answer that question.

Yoshino’s 2021 Washington University trial found improved skeletal muscle insulin sensitivity with 250 mg/day NMN in postmenopausal women with prediabetes who were overweight or obese. That was a positive metabolic signal, but it came from a small, specific population and has not been replicated at scale. A 2021 trial in amateur runners also found that oxygen utilization in skeletal muscle improved compared with placebo. Its sample was small and relatively young.

How a 2026 head-to-head trial changed the mechanistic story

Cuenoud and colleagues’ 2026 randomized, placebo-controlled trial in Nature Metabolism compared NMN, NR, and nicotinamide in 65 healthy adults. It was the first direct human comparison of multiple NAD+ precursors. Both NMN and NR approximately doubled circulating NAD+ after a short supplementation period, while nicotinamide produced only an acute, transient effect. The two supplements were not meaningfully differentiated by their sustained NAD+-raising ability. The surprise was how that elevation occurred.

The trial found that gut bacteria were largely responsible for the sustained rise, rather than direct absorption in the way earlier models had assumed. Gut microbes convert NMN and NR to nicotinic acid, a potent NAD+ precursor that then drives the sustained blood increase. This changes the interpretation of a dose. The amount swallowed is one part of the process, while microbial conversion is another.

The same trial found that NR, but not nicotinamide, increased short-chain fatty acids and total gut bacterial density. Those metabolites have shown anti-inflammatory, anti-diabetes, and anti-cancer effects in rodent models, but the same benefits have not been shown in these participants. If microbiome composition affects conversion, differences between people who get the same dose may reflect their biology. No trial has yet systematically addressed that question, leaving future research to examine who converts these precursors effectively and whether that predicts functional benefit.

Where NMN and NR fall short: metabolic and muscle outcomes in controlled trials

Chen and colleagues’ meta-analysis brought together eight randomized controlled trials with 342 middle-aged and older adults. The trials studied NMN at dosages from 250 mg/day upward for periods of up to 12 weeks. The analysis found no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, insulin resistance, or lipid profile. The pooled metabolic results were plainly negative. The earlier insulin-sensitivity finding thus points to a benefit in that group, but it does not show that glucose control improves more widely.

A 2025 systematic review and meta-analysis of NMN and NR in adults over 60 found no statistically significant effect on any of the muscle outcomes it assessed. Skeletal muscle index, handgrip strength, gait speed, and chair stand tests all showed null results. Its authors concluded that “Current evidence does not support the use of NMN and NR as effective interventions for improving muscle function and mass in adults above 60 years old”. That is a direct challenge to supplement marketing. Sarcopenia, or age-related muscle loss, is one of the prominent conditions used to promote NAD+ supplements, yet the aggregated human evidence does not support that use.

Could longer trials produce a different result? Most studies had few participants and were short, often lasting 8–12 weeks, and they did not track hard disease endpoints over longer periods. Supplement proponents still bear the burden of demonstrating benefit, especially when the proposed first step, NAD+ elevation, has already been shown to occur. Repeated null functional results limit the claims that can be made, while leaving open the chance that the supplements could help in more specific settings.

Where the evidence is more promising: cardiovascular markers and a specific Long COVID application

One NR trial found that blood NAD+ approximately doubled and systolic blood pressure fell meaningfully in participants whose pressure was elevated at baseline. The direction and magnitude were notable for a short-duration study, but the effect was not statistically significant after correction for multiple comparisons. That qualification changes the strength of the conclusion. The result gives researchers a reason to test whether NR lowers blood pressure, but it does not show that NR works for this use.

A 12-week double-blind, placebo-controlled trial studied 250 mg/day NMN in 36 healthy middle-aged adults. The trial found significantly elevated serum nicotinamide and a tendency toward lower pulse wave velocity, a measure of arterial stiffness. But it found no statistically significant difference between the groups. The trial also reported good tolerability with no adverse events within the study.

Wu and colleagues’ 2025 trial in eClinicalMedicine tested NR in Long COVID and found that NAD+ rose substantially after 5–10 weeks and was still high at 20 weeks. Exploratory post-hoc analyses found that fatigue, sleep, depression symptoms, and some executive function tasks improved among people who took NR for at least 10 weeks. The randomized comparison found no significant differences in cognitive scores, fatigue, sleep, or mood between the treatment and placebo groups. That comparison deserves priority over the subgroup findings. Critics also flagged the trial as underpowered and affected by a high dropout rate, making the apparent improvements hypothesis-generating.

What links these signals to the earlier prediabetes finding? They tend to arise in people with a defined pathological starting condition, including elevated blood pressure, Long COVID, or prediabetes. That pattern suggests that supplements might help people with specific conditions, but it gives no basis for everyone to take them. It does not establish which group will benefit. The next evidentiary step is replication of a specific improvement in a clearly defined population.

What the regulatory history of NMN reveals about how supplement markets work

The FDA reversed its prior position in two letters dated September 29, 2025, confirming that NMN was not excluded from the definition of a dietary supplement. The dispute had concerned NMN’s classification, and the earlier position had effectively removed products from the market. The agency reinstated NMN’s New Dietary Ingredient status that day. It then sent follow-up letters on December 2, 2025, formally reinstating individual notifications for specific ingredient suppliers.

Australia’s TGA approved NMN in December 2025. The EU has completed its EFSA safety evaluation but has not yet issued final authorization under its Novel Food framework, leaving a fragmented regulatory landscape. These decisions do not establish anti-aging benefits. NMN is a supplement, and its NDI status does not make it an FDA-approved drug or imply that it treats, prevents, or cures any condition. The three-year U.S. regulatory limbo generated market confusion without generating new safety or efficacy data, so its resolution should not be read as scientific vindication.

What a proactive person who is considering NMN or NR should actually track

For someone choosing to supplement despite these uncertainties, the practical lesson is to treat it as a measured personal experiment. That starts with separating the biological response from the desired benefit. Commercial blood NAD+ testing can provide a personal baseline, but current guidelines offer no clinical reference range for an “optimal” level. A number alone is not a treatment target. Even a clear increase would show only that the supplement changed that marker.

Monitoring can draw on the outcomes used in trials. Fasting insulin and glucose provide metabolic measures relevant to the insulin-sensitivity signal, while blood pressure or pulse wave velocity addresses the cardiovascular findings. hsCRP offers an inflammatory measure, though its rationale here is weaker because the relevant short-chain fatty acid effects come from rodent models. These markers do not have equal evidentiary support. Before-and-after assessment through a clinician or direct-access service can make an experiment more informative, but the choice of measure should stay tied to the question being asked.

A change in a biomarker is not proof of improved healthspan, just as a higher blood NAD+ reading is not proof of stronger muscles. The studies so far do not show which product or dosing protocol to use in clinical care. Someone choosing NMN or NR is therefore making a bet on a plausible mechanism, with stronger evidence for biochemical activity than for practical benefit.